Mahmood, UmairBlake, AndrewRathee, SanjaySamuel, LeslieMurray, GraemeSebag-Montefiore, DavidGollins, SimonWest, Nicholas PBegum, RubinaBach, Simon PRichman, Susan DQuirke, PhilRedmond, Keara LSalto-Tellez, ManuelKoelzer, Viktor HLeedham, Simon JTomlinson, IanDunne, Philip DBuffa, Francesca MMaughan, Tim SDomingo, Enric2024-07-222024-07-222024-07-18Mahmood, U, Blake, A, Rathee, S, Samuel, L, Murray, G, Sebag-Montefiore, D, Gollins, S, West, N P, Begum, R, Bach, S P, Richman, S D, Quirke, P, Redmond, K L, Salto-Tellez, M, Koelzer, V H, Leedham, S J, Tomlinson, I, Dunne, P D, Buffa, F M, Maughan, T S & Domingo, E 2024, 'Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and Transcriptional Signatures', Cancer research communications, vol. 4, no. 7, pp. 1765-1776. https://doi.org/10.1158/2767-9764.CRC-23-05022767-9764PubMedCentral: PMC11257085ORCID: /0000-0002-8402-8670/work/164096064https://hdl.handle.net/2164/23876Acknowledgments This research from the MRC/CRUK project S:CORT consortium was funded by the UKRI (MR/M016587/1). The ARISTOTLE trial was funded by Cancer Research UK (CRUK/08/032). F.M. Buffa and S. Rathee also received funding from ERC Consolidator Grant 772970 (Micro-C). Members of the S:CORT consortium are listed in the Supplementary Data (S:CORT consortium authors list). For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.123468175engSDG 3 - Good Health and Well-beingHumansRectal Neoplasms/pathologyNeoadjuvant TherapyMaleFemaleTranscriptomeMiddle AgedAgedCapecitabine/therapeutic useFluorouracil/therapeutic useGene Expression ProfilingOxaliplatin/therapeutic useAntineoplastic Combined Chemotherapy Protocols/therapeutic useGene Expression Regulation, Neoplastic/drug effectsR MedicineUK Research and Innovation (UKRI)MR/M016587/1Cancer Research UKCRUK/08/032Supplementary Datahttps://aacrjournals.org/cancerrescommun/RJournal article10.1158/2767-9764.CRC-23-050247